Yahoo
Tokyo - Delayed Quote JPY

JCR Pharmaceuticals Co., Ltd. (4552.T)

496.00 +8.00 (+1.64%)
At close: 3:30:00 PM GMT+9
View in AlphaSpace Currency in JPY All numbers in thousands
Financial statements have been upgraded
A new layout with more detail in every statement.
TTM
3/31/2026
3/31/2025
3/31/2024
3/31/2023
Total Revenue
41,450,000 40,319,000 33,072,000 42,871,000 34,343,000
Cost of Revenue
-10,026,000 -10,134,000 -10,902,000 -11,620,000 -8,886,000
Gross Profit
31,423,000 30,185,000 22,169,000 31,251,000 25,456,000
Operating Income/Expenses
-32,365,000 -29,629,000 -28,389,000 -23,719,000 -20,480,000
Total Operating Profit/Loss
-942,000 556,000 -6,220,000 7,532,000 4,976,000
Total Net Finance Income/Expense
-397,000 -317,000 -42,000 25,000 -11,000
Net Investment Income
1,286,000 1,226,000 -628,000 -297,000 418,000
Irregular Income/Expenses
1,726,000 1,725,000 871,000 -20,000 -16,000
Other Income/Expense, Non-Operating
219,000 35,000 35,000 5,000 44,000
Non-Operating Income/Expenses, Total
2,834,000 2,669,000 236,000 -287,000 435,000
Pretax Income
1,891,000 3,224,000 -5,983,000 7,244,000 5,412,000
Provision for Income Tax
-1,031,000 -1,017,000 1,586,000 -1,707,000 -1,625,000
Net Income from Continuing Operations
860,000 2,207,000 -4,397,000 5,537,000 3,787,000
Net Income after Extraordinary Items and Discontinued Operations
859,000 2,207,000 -4,396,000 5,536,000 3,787,000
Non-Controlling/Minority Interests
-42,000 -28,000 -63,000 -28,000 -14,000
Net Income after Non-Controlling/Minority Interests
817,000 2,178,000 -4,460,000 5,507,000 3,772,000
Net Income Available to Common Stockholders
817,000 2,178,000 -4,460,000 5,507,000 3,772,000
Diluted Net Income Available to Common Stockholders
817,000 2,178,000 -4,460,000 5,507,000 3,772,000
Basic EPS
6.71 17.87 -36.02 44.13 30.35
Diluted EPS
6.70 17.86 -36.02 43.92 30.22
Basic Weighted Average Shares Outstanding
121,984.37 121,941.61 123,825.56 124,790.39 124,283.36
Diluted Weighted Average Shares Outstanding
121,991.25 121,948.49 126,708.08 125,387.07 124,818
Income Statement, Supplemental
EBIT
2,288,000 3,541,000 -5,941,000 7,219,000 5,423,000
EBITDA
6,098,000 6,098,000 -2,567,000 10,416,000 7,420,000
Normalized EBITDA
3,934,000 3,934,000 -2,888,000 10,863,000 6,640,000
Normalized Income
-352,687.60 1,165,000 -7,477,000 7,264,000 5,418,000
Total Unusual Items
-1,726,000 -2,164,000 -321,000 447,000 -780,000
Total Unusual Items Excluding Goodwill
-1,726,000 -2,164,000 -321,000 447,000 -780,000
Tax Effect of Unusual Items
-513,312.40 -682,627.31 -85,091.96 105,492 -234,000
3/31/2023 - 11/17/2005

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: